Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29737250 | 1.00 | PNMT (0.67) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL30051168 | 0.84 | CYP1A2 (0.52) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL3786158 | 0.84 | CYP1A2 (0.52) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL1170186 | 0.84 | CYP1A2 (0.52) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL11505568 | 0.83 | CYP1A2 (0.50) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| Methane SCHEMBL27575665 | 0.83 | CYP1A2 (0.50) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL23203567 | 0.81 | CYP1A2 (0.48) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL8207165 | 0.80 | PNMT (1.00) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL158333 | 0.80 | PNMT (1.00) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL8207792 | 0.80 | PNMT (1.00) | PNMTCYP1A2CYP3A4CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964509-B1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | NANJING HEPO PHARMACEUTICAL CO LTD (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-3964509-B1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | NANJING HEPO PHARMACEUTICAL CO LTD (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2023-05-30 | — | — | US | disclosed |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20220213085-A1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| CN-111848601-B | Compound containing condensed ring, application thereof and pharmaceutical composition containing compound | 南京海璞医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3964509-A1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Nanjing Hepo Pharmaceutical Co., Ltd (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-111848601-A | Compound containing condensed ring, application thereof and pharmaceutical composition containing compound | 南京海璞医药科技有限公司 | 2020-10-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213085-A1 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HLA-B, HLA-A, SLC10A1 | PNMT 4629/4885CYP1A2 645/4885CYP3A4 86/4885 |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | HLA-B, HLA-A, SLC10A1 | PNMT 4629/4885CYP1A2 645/4885CYP3A4 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.